Eton Pharmaceuticals Reports Third-Quarter 2026 Financial Results
Eton reported results for the quarter ended September 30, 2026.
Story updates
09:37:29 PM UTC
SquawkNews
Eton Pharmaceuticals’ third-quarter revenue rose year over year, and the company swung to a profit from a loss. Growth was driven by HEMANGEOL’s acquisition and higher sales of several products, while lower INCRELEX sales outside the U.S. partly offset gains; a $12.9 million income tax benefit also…
DEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) NASDAQ:ETON, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2026…